In good faith we give approval with the following issues to be refined. I have sent some comments previously to RR and GC  and they have responded to them. I still have concerns on Slide 18 and the  >90% inhibition comment - we believe that this will be taken out of context unless its clearly identified that the concentration used was dramatically higher than the compounds that achieved 30%.  Yes these are short term experiments but a third party journalist will simply say that we have inhibitors that give a 90% reduction - when we don't. We have not at this point continued our work with that compound and so I think its misleading. As the organisation commercializing this work I would request that the number doesn't appear on a slide but if you wish to note verbally a 90% reduction in the short term has been observed with some early compounds then perhaps that is a reasonable compromise. 
As noted also we are interested in further development of PD- can you please provide the final text of the paper that relates to this point I would like to be aware of what emphasis has been put on this. 
I would also ask that given your  audience that a concluding point is made that the outputs of this work will be commercialized by the PGGRC and interested parties should contact us to discuss further. 